samedan logo
 
 
 
spacer
home > ebr > summer 2007 > rising to the challenge: metabolomics in disease and drug development
PUBLICATIONS
European Biopharmaceutical Review

Rising to the Challenge: Metabolomics in Disease and Drug Development

Steven Fischer at Agilent Technologies describes the pitfalls associated with metabolomics research and the new tools developed to overcome them

Metabolomics is a developing analytical approach that is rapidly growing in importance as a tool to improve the diagnosis and treatment of disease, as well as to speed up the drug development process. Unlike genomics or proteomics, which only reveal part of what might be happening in a cell, metabolomic profiling can give an instantaneous snapshot of the entire physiology of that cell. In drug development, most pharmaceutical companies are constantly searching for ways to speed up this process and to reduce cost. This means that problems with compounds that would make unsuitable drug candidates should be identified as quickly as possible.

The objective is to find those few molecules that have the right biochemical properties to become the next blockbuster drug by sifting through the failures to find the few successes. Efficacy and toxicology are important issues in getting a drug to market. Metabolomics can be used to discover biomarkers to track drug efficacy or uncover potential toxic side effects in lead compounds at the molecular level.

SEPARATION CHALLENGES FOR METABOLOMICS

Separation is an important part of metabolomics because the samples are complex. The chemical information in the retention or migration time of the separation is used to track and identify a metabolite undergoing analysis. This is necessary because mass spectrometry (MS) alone cannot distinguish isobaric metabolites, whereas chromatography can be used to separate and identify isomers. The two most commonly used separation techniques are gas chromatography (GC) and liquid chromatography (LC).

Gas chromatography and mass spectrometry (GC/MS) is an effective combination for the analysis of volatile chemicals. Metabolites, therefore, must be volatile or amenable to chemical derivatisation to render them volatile to be analysed by GC/MS. Certain types of samples are particularly well suited to GC/MS analyses (see Figure 1). These include plant terpenes and essential oils, which are volatile and do not ionise well by liquid chromatography/mass spectrometry (LC/MS) techniques.

Other analytes generally compatible with GC/MS include steroids, diglycerides, mono-, di- and trisaccharides, and sugar alcohols. Liquid chromatography can separate metabolites that are not volatile without derivatisation. As a result, LC/MS can analyse a much wider range of chemical species


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steven Fischer studied Chemistry at California State University, Hayward. In 1986, he joined Agilent Technologies in Santa Clara (previously part of Hewlett-Packard Company), where he has designed and applied HPLC/MS instrumentation for analytical problems for 16 years. He has over 40 issued patents in the field of mass spectrometry. Recently, he has focused his attention on the challenges of metabolomics analysis and is currently a Senior Applications Chemist for Metabolomics, actively developing solutions for metabolomics using mass spectrometry.
spacer
Steven Fischer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Creating your Secondary Packaging Strategy

Pharmaceutical and biotechnology companies with a drug product in clinical development are usually focused on a quick commercial launch. Secondary packaging aspects are often less considered. Correlations with secondary packaging (in this context, secondary packaging also includes device assembly and serialization) that are not considered in this phase can have a negative effect on: further processability options in the product lifecycle management cost and time-to-market
More info >>

White Papers

Sterile Vials Made of Tubular Glass

Gerresheimer AG

Gx RTF vials powered by Ompi EZ-fill enhance flexibility by facilitating packaging needs from clinical stage to industrialization with the common goal to minimize customer product risks and optimize total cost of ownership. Gerresheimer combines the competencies in converting glass tubes to serum/ injection vials and ready-to-fill processing for our pharma and biotech customers.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement